M-3554 is an antibody-drug conjugate (ADC) targeting GD2; it has shown strong antitumor activity in neuroblastoma xenograft models and has been engineered to reduce anti-GD2 antibody-associated pain.
Phrontline Biopharma Suzhou Co. Ltd. closed a $60 million pre-A+ financing round led by Lapam Investment, with participation from nine other investors. The funds raised will support Phrontline’s development of next-generation antibody-drug conjugate (ADC) candidates.
Two South Korean conglomerates – Samyang Holdings Corp. and Samsung Biologics Co. Ltd. – listed their newly spun-off biopharmaceutical units on Korea Exchange’s (KRX) main trading board Nov. 24.
Crossbridge Bio Inc. has been awarded a $15 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support completion of IND-enabling activities and advancement of CBB-120 into first-in-human studies.
Researchers at Tubulis GmbH reported preclinical efficacy data on TUB-030, a novel 5T4-targeting antibody-drug conjugate (ADC), in several sarcoma subtypes.
Antengene Corp. Ltd. has outlined progress in its early-stage pipeline. The company has leveraged its Antengager T-cell engager (TCE) platform for the discovery of multiple investigational programs.
Hutchmed Ltd. has identified antibody-drug conjugates comprising an antibody or antigen binding fragment covalently linked to a GTPase RAS or KRAS inhibitor through a linker reported to be useful for the treatment of cancer.
Although tricomplex pan-RAS (ON) inhibitors, such as RMC-6236, constitute a promising class of therapeutics against RAS-driven cancers, their on-target, off-tumor toxicities challenge the dosing strategy and the safety of drug combinations.
CIS Biopharma AG recently presented an antibody-drug conjugate (ADC) targeting the L1 cell adhesion molecule (L1CAM/CD171) as a potential candidate for the treatment of advanced tumors.
RSS
